We here by submit Financial Results (Standalone and Consolidated) for the Quarter and Year ended 31.03.2026 along with Auditors Report thereon. Kindly take the same on your records.

Profit growth above 25%Exceptional itemRelated-party transactionsResults View source PDF Explain this filing

AMBALALSA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹32.81

prior close

₹33.60

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+1.3% vs market

Pharmaceuticals peers, median of 164sector-0.1%+1.5% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+2.7

15m

+2.1

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+0.1+1.3-0.1+1.5

Next day

-1.0+1.7-2.7+0.9-1.9

+0.2+2.4-2.2+0.9-0.7

+6.6+2.4+4.3+0.7+5.9

+8.5+1.7+6.8+0.8+7.7

+8.6+0.6+8.0+0.0+8.6

+8.8+1.9+6.9-0.1+8.9

15d

+0.7+4.9-4.2+1.2-0.4

-3.4+8.9-12.3+3.0-6.4

-4.4+7.5-11.9+4.7-9.1

+34.1+13.6+20.5+7.9+26.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Ambalal Sarabhai Enterprises reported strong FY2026 results with consolidated revenue of Rs 20,227L (up 3.1% YoY) and PAT of Rs 1,780L, a 261% jump from Rs 493L in FY2025. Standalone PAT grew 33% to Rs 1,099L from Rs 824L. The improvement was driven by reversal of provisions (Rs 520L), settlement gains, and improved operating performance in both Pharmaceuticals and Electronics segments. Exceptional items include Rs 460L litigation reversal (standalone) and Rs 82L labour code adjustment (consolidated). The Board approved intercorporate loans to three subsidiaries and reappointed key promoters including Executive Chairman and Managing Director.

Likely market impact

The company delivered exceptional PAT growth in FY2026, driven largely by one-time gains and provisions reversals. Shareholders should note the loans to related parties and ongoing labour code adjustments that may impact future earnings.